Rein Therapeutics Inc.
RNTX
$1.27
$0.1412.39%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 0.94% | 3.23% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 22.50% | -3.24% | |||
| Operating Income | -22.50% | 3.24% | |||
| Income Before Tax | -24.01% | 87.06% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -24.01% | 86.58% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -24.01% | 86.58% | |||
| EBIT | -22.50% | 3.24% | |||
| EBITDA | -22.83% | 3.51% | |||
| EPS Basic | -12.35% | 86.71% | |||
| Normalized Basic EPS | -12.36% | 1.44% | |||
| EPS Diluted | -12.35% | 86.71% | |||
| Normalized Diluted EPS | -12.36% | 1.44% | |||
| Average Basic Shares Outstanding | 10.37% | 1.03% | |||
| Average Diluted Shares Outstanding | 10.37% | 1.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||